MA56220A - Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil - Google Patents

Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil

Info

Publication number
MA56220A
MA56220A MA056220A MA56220A MA56220A MA 56220 A MA56220 A MA 56220A MA 056220 A MA056220 A MA 056220A MA 56220 A MA56220 A MA 56220A MA 56220 A MA56220 A MA 56220A
Authority
MA
Morocco
Prior art keywords
medicines
eye
delivery
protection
anterior segment
Prior art date
Application number
MA056220A
Other languages
English (en)
French (fr)
Inventor
David P Bingaman
Paul G Chaney
Martin B Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MA56220A publication Critical patent/MA56220A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056220A 2014-09-17 2015-09-17 Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil MA56220A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
MA56220A true MA56220A (fr) 2022-04-20

Family

ID=55453708

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056220A MA56220A (fr) 2014-09-17 2015-09-17 Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil

Country Status (19)

Country Link
US (6) US9814702B2 (enExample)
EP (2) EP3878449B1 (enExample)
JP (3) JP6657193B2 (enExample)
KR (2) KR102450020B1 (enExample)
CN (2) CN113209000B (enExample)
AU (2) AU2015317531B2 (enExample)
CA (1) CA2958315A1 (enExample)
DK (1) DK3193867T3 (enExample)
ES (2) ES3010497T3 (enExample)
HU (1) HUE053852T2 (enExample)
IL (2) IL282504B (enExample)
MA (1) MA56220A (enExample)
MX (2) MX383792B (enExample)
NZ (1) NZ767710A (enExample)
PL (1) PL3193867T3 (enExample)
PT (1) PT3193867T (enExample)
RU (2) RU2704810C2 (enExample)
WO (1) WO2016044671A1 (enExample)
ZA (1) ZA201701303B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
SG11201907400YA (en) * 2018-07-18 2020-02-27 Univ Wenzhou Medical Method for treating myopia and application in preparation of medicament
EP3870204A4 (en) * 2018-10-24 2022-12-21 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics formulations
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053806A1 (en) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
YU36403A (sh) * 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
RU2012105453A (ru) 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
EP2482677A1 (en) * 2009-09-30 2012-08-08 The Regents of The University of California Cofactors and methods for use for individuals
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドOhr Pharmaceutical,Inc. スクアラミンの眼用製剤
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
SG11201507316UA (en) * 2013-03-14 2015-10-29 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil

Also Published As

Publication number Publication date
PT3193867T (pt) 2021-03-09
JP6657193B2 (ja) 2020-03-04
RU2017112930A (ru) 2018-10-17
KR102450020B1 (ko) 2022-09-30
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
ES3010497T3 (en) 2025-04-03
IL282504B (en) 2022-08-01
EP3193867A4 (en) 2018-05-02
MX2017003436A (es) 2017-07-28
MX383792B (es) 2025-03-14
US20160206599A1 (en) 2016-07-21
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
IL282504A (en) 2021-06-30
JP2021121624A (ja) 2021-08-26
ES2863601T3 (es) 2021-10-11
HUE053852T2 (hu) 2021-07-28
US20210275501A1 (en) 2021-09-09
DK3193867T3 (da) 2021-04-06
US20190314343A1 (en) 2019-10-17
PL3193867T3 (pl) 2021-07-12
RU2017112930A3 (enExample) 2019-04-11
KR20220137157A (ko) 2022-10-11
EP3878449A1 (en) 2021-09-15
US9814702B2 (en) 2017-11-14
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
JP7176042B2 (ja) 2022-11-21
JP2020079274A (ja) 2020-05-28
MX2021006070A (es) 2021-07-06
WO2016044671A1 (en) 2016-03-24
JP2017527600A (ja) 2017-09-21
AU2015317531B2 (en) 2020-11-19
CN113209000B (zh) 2025-05-13
JP6890692B2 (ja) 2021-06-18
AU2021200997A1 (en) 2021-03-11
US10183014B2 (en) 2019-01-22
US20160074371A1 (en) 2016-03-17
IL251019B (en) 2021-05-31
US20240277674A1 (en) 2024-08-22
IL251019A0 (en) 2017-04-30
RU2704810C2 (ru) 2019-10-31
ZA201701303B (en) 2021-07-28
EP3193867B1 (en) 2021-01-20
US9623011B2 (en) 2017-04-18
NZ729142A (en) 2023-08-25
RU2768652C1 (ru) 2022-03-24
KR102555091B1 (ko) 2023-07-13
CN106999476A (zh) 2017-08-01
US20180078531A1 (en) 2018-03-22
NZ767710A (en) 2023-09-29
CN106999476B (zh) 2021-05-04
EP3878449B1 (en) 2024-10-30
KR20170058976A (ko) 2017-05-29

Similar Documents

Publication Publication Date Title
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
EP3713530A4 (en) OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT
EP3291765A4 (en) METHOD FOR THE DELIVERY OF AN ACTIVE SUBSTANCE TO THE EYE
GB201704211D0 (en) Ophthalmic delivery device and ophthalmic drug compositions
IL253195B (en) Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
EP3621656A4 (en) FORMULATION FOR THE ADMINISTRATION OF AN EYE MEDICINE
EP3310343A4 (en) IMPLANTABLE MEDICAMENT DELIVERY COMPOSITIONS AND METHOD FOR USE THEREOF
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
EP3389591C0 (en) Medical delivery device
PL3413872T3 (pl) Nieinwazyjna wkładkowa technologia podawania leków do oka
EP3348206A4 (en) DEVICE FOR RELEASING A THERAPEUTIC ACTIVE DEVICE AND KIT FOR RELEASING A THERAPEUTIC AGENT
EP3721890A4 (en) OPHTHALMIC DRUG PREPARATION AND ITS USES
EP3238746A4 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
EP3203995A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
GB2558494B (en) Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
EP3458030A4 (en) DEVICE FOR RENEIDING MEDICINAL PRODUCT
EP3319549A4 (en) ACTIVE RELEASE DEVICE
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
HUE069481T2 (hu) Technológia nem invazív szemészeti gyógyszerek bejuttatására